CN104367947A - Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat - Google Patents
Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat Download PDFInfo
- Publication number
- CN104367947A CN104367947A CN201410626365.5A CN201410626365A CN104367947A CN 104367947 A CN104367947 A CN 104367947A CN 201410626365 A CN201410626365 A CN 201410626365A CN 104367947 A CN104367947 A CN 104367947A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- pharmaceutical composition
- panacis majoris
- rhizoma panacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat. The pharmaceutical composition is prepared from rhubarb roots, radix curcumae, crataegus pinnatifida, polygonum multiflorum, bombyx batryticatus, rhizoma panacis majoris and laminaria. Proofed by pharmacological experiments, the pharmaceutical composition disclosed by the invention has a very good blood fat lowering effect, is definite in treatment effect, low in drug dosage and simple in prescription, is free from toxic or side effects on human bodies and is beneficial to popularization and application.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of blood fat reducing, particularly a kind of is the pharmaceutical composition that raw material is made by Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae).
Background technology
Along with improving constantly of people's living standard, the sickness rate of hyperlipemia is obvious ascendant trend, and hyperlipemia is again the key factor of bringing out coronary atherosclerotic heart disease (coronary heart disease), arteriosclerosis, fatty liver, diabetes, obesity etc.Therefore the blood lipid-lowering medicine finding high effect nontoxic has important realistic meaning.
Lipoprotein refers to the protein together with contaminated with lipid, comprise very low density lipoprotein (VLDL) (VLDL), low density lipoprotein, LDL (LDL), high density lipoprotein (HDL), the lipid of different lipoprotein forms the difference mainly measured, the difference of rarer matter.The chemical composition 80% ~ 90% of very low density lipoprotein (VLDL) is triacylglycerol, is the important form of body transport endogenous triacylglycerol, so when very low density lipoprotein (VLDL) raises, triacylglycerol also must raise; Low density lipoprotein, LDL is that its molecule is minimum, and cholesterol level is the highest, so when low density lipoprotein, LDL increases, cholesterol total amount must increase by the principal mode of the cholesterol transport of liver synthesis to body tissue; High density lipoprotein granule is less, protein content is the highest, can more freely to come in and go out tremulous pulse, can excrete after carrying out metabolism in the reverse cholesterol transport on arterial wall to liver, reduce the deposition of cholesterol on arterial wall, the minimizing of high density lipoprotein just means increasing of cholesterol total amount.
The Western medicine being used for the treatment of hyperlipemia is at present subject to everybody favor certainly because of its rapid-action and curative effect, but Western medicine has toxic and side effects in various degree, and Chinese medicine is in treatment hyperlipemia, prevent the aspects such as cardiovascular and cerebrovascular disease generation from having unique advantage, its curative effect certainly, lasting, side effect is little, is that Western medicine institute is incomparable.Particularly in differentiation of symptoms and signs for classification of syndrome, embody the flexible prescription of the traditional Chinese medical science, the therapeutic features of giving treatment in accordance with the patient’s individuality.Modern doctor generally believes genus deficiency in origin and excess in superficiality, blood stasis, the turbid category of expectorant for the understanding of hyperlipemia; Ahyperlipoidemia name of disease in Chinese medicine, clinical syndrome differentiation is attributed to caused by liver and kidney deficiency more, and insufficiency of the spleen expectorant is turbid, qi depression to blood stasis.Large multiplex liver and kidney tonifying during treatment, invigorating the spleen and benefiting QI, nourishing YIN and benefiting blood, blood circulation promoting and blood stasis dispelling, clearing away heat and loosing the bowels, eliminate indigestion and phlegm these medicines.
At present, treatment hyperlipemia Chinese patent medicine more, this wherein, some prescriptions are excessive, and curative effect is indefinite, and what have causes price quite high owing to employing rare medicinal herbs in side.These all make to be unfavorable for that promotion price is applied.
Summary of the invention
The object of the invention is to overcome above-mentioned deficiency existing in prior art, a kind of pharmaceutical composition for blood fat reducing containing Rhizoma Panacis Majoris is provided.This pharmaceutical composition has good blood fat reducing function, determined curative effect, and dosage is little, and to human non-toxic's side effect, and prescription is simple, is beneficial to and applies.
In order to realize foregoing invention object, the invention provides following technical scheme:
The pharmaceutical composition for blood fat reducing containing Rhizoma Panacis Majoris of the present invention, it is the medicament be made up of following raw material: Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae).
In pharmaceutical composition of the present invention, Radix Et Rhizoma Rhei bitter in the mouth, cold in nature, return spleen, stomach, large intestine, liver, pericardium channel.Purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.For excess-heat constipation, stagnant stomachache, dysentery is not well, jaundice due to damp-heat, and heat in blood tells nosebleed, conjunctival congestion, pharyngeal swelling, abdominalgia with intestinal abscess, carbuncle furuncle, blood stasis amenorrhea, traumatic injury, burn due to hot liquid or fire; Upper gastrointestinal hemorrhage.
Radix Curcumae acrid in the mouth, hardship, cold in nature.Return liver, the heart, lung meridian, there is the use of regulating qi to disperse stagnation, heart fire-clearing upset-relieving, promoting the function of the gallbladder to alleviate jaundice, promoting blood circulation and stopping pain, promoting QI circulation for relieving depression, the removing heat from blood that clears away heart-fire.
Fructus Crataegi, acid is sweet, tepor.Enter spleen, stomach, Liver Channel.Help digestion long-pending, dissipating blood stasis blood, expelling tenia.Control meat to amass, lump in the abdomen, phlegm retention, feeling of fullness, acid regurgitation, dysentery, hemorrhoidal hamorrhage, lumbago, hernia after-pains in puerperal, lochiorrhea, children's's breast food is stagnated.Promoting digestion and invigorating the stomach, circulation of qi promoting dissipating blood stasis.For meat stagnation, stomach alkane distension, dysentery stomachache, blood stasis amenorrhea, postpartum stagnation, trusted subordinate's twinge, hernia pain, hyperlipidemia.
Radix Polygoni Multiflori, bitter sweet puckery, tepor.Enter liver, kidney channel.Nourishing the blood and yin; Loosening bowel to relieve constipation; Preventing the attack (or recurrence) of malaria; Dispel the wind; Removing toxic substances.Main blood deficiency Light-headedness; Cardiopalmus; Insomnia; The soreness of the waist and knees of the hepatic and renal YIN deficiency; Early whitening of beard and hair; Tinnitus; Seminal emission; Dryness of the intestine constipation; Chronic malaria body is empty; Rubella pruritus; Carbuncle sore; Scrofula; Hemorrhoid.
Bombyx Batryticatus, salty, pungent, flat, return liver, lung, stomach warp.Be mainly used in convulsion with spasms, laryngopharynx swelling and pain, submandibular lymph nodes is scorching, facial paralysis, the diseases such as skin pruritus.
Rhizoma Panacis Majoris, bitter, sweet, be slightly cold.Return liver, lung, stomach warp.Tonifying the lung, yin nourishing, active, hemostasis; For deficiency of both QI and YIN, dysphoria with smothery sensation is thirsty, cough due to consumptive disease, injury from falling down, arthralgia, hemoptysis, spits blood, traumatic hemorrhage.There is antiinflammatory, slow down aging, the effects such as blood sugar lowering.
Thallus Laminariae (Thallus Eckloniae), beam " Mingyi Bielu " is said: salty in the mouth, cold, nontoxic.Cure mainly 12 kinds of edema, the coalescent gas of goiter, fistula skin ulcer.The raw East Sea.
Applicant finds through test of many times, is that pharmaceutical composition made by raw material by Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae), can effectively blood fat reducing.
Preferably, described pharmaceutical composition is made up of the raw material of following weight: Radix Et Rhizoma Rhei 5 ~ 18 parts, Radix Curcumae 6 ~ 20 parts, Fructus Crataegi 1 ~ 15 part, Radix Polygoni Multiflori 4 ~ 15 parts, Bombyx Batryticatus 1 ~ 10 part, Rhizoma Panacis Majoris 1 ~ 10 part and Thallus Laminariae (Thallus Eckloniae) 1 ~ 8 part.
Applicant finds through many experiments, and pharmaceutical composition of the present invention is made up of the raw material of above-mentioned weight, better can play the synergistic function of each raw material components, not only can effectively blood fat reducing, simultaneously instant effect, and dosage is little, has no side effect.
Further preferably, described pharmaceutical composition is made up of the raw material of following weight: Radix Et Rhizoma Rhei 6 ~ 15 parts, Radix Curcumae 6 ~ 14 parts, Fructus Crataegi 1 ~ 12 part, Radix Polygoni Multiflori 5 ~ 12 parts, Bombyx Batryticatus 4 ~ 8 parts, Rhizoma Panacis Majoris 2 ~ 7 parts and Thallus Laminariae (Thallus Eckloniae) 1 ~ 5 part.
Still more preferably, described pharmaceutical composition is made up of the raw material of following weight: Radix Et Rhizoma Rhei 8 ~ 10 parts, Radix Curcumae 7 ~ 12 parts, Fructus Crataegi 5 ~ 10 parts, Radix Polygoni Multiflori 8 ~ 10 parts, Bombyx Batryticatus 5 ~ 6 parts, Rhizoma Panacis Majoris 3 ~ 6 parts and Thallus Laminariae (Thallus Eckloniae) 2 ~ 4 parts.
Preferably, to the best described pharmaceutical composition be made up of the raw material of following weight: Radix Et Rhizoma Rhei 9 parts, Radix Curcumae 9 parts, Fructus Crataegi 9 parts, Radix Polygoni Multiflori 9 parts, Bombyx Batryticatus 6 parts, Rhizoma Panacis Majoris 5 parts and Thallus Laminariae (Thallus Eckloniae) 3 parts.
By preferably above, the curative effect of pharmaceutical composition can be improved further.
The dosage form of pharmaceutical composition of the present invention can be the existing pharmaceutical dosage form of any one in drop pill, tablet, capsule, soft capsule, powder, oral liquid, granule.
The preparation method of pharmaceutical composition of the present invention is as follows:
(1) get Radix Et Rhizoma Rhei, add the water reflux, extract, 10 hours of 8-12 times of volume, collect extracting solution, concentrated, dry, obtain Radix Et Rhizoma Rhei extract.
(2) get Radix Curcumae, add ethanol 55 DEG C of lixiviates 3 times of 60 ~ 80% of 8-10 times of volume, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Curcumae extract.
(3) get Fructus Crataegi, pulverize, use mechanical lapping process, the water adding 8-10 times of volume extracts 2 times at 35 DEG C, each 3h, merge extractive liquid, gets supernatant after centrifugal, adds ethanol to 60% and precipitates, centrifugal removing supernatant, collecting precipitation, vacuum lyophilization, obtains Fructus Crataegi extract.
(4) get Radix Polygoni Multiflori, add ethanol 60 DEG C of lixiviates 3 times of 80% of 8-10 times of volume, each 2 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Polygoni Multiflori extract.
(5) get Bombyx Batryticatus, rub, add ethanol 50 DEG C of lixiviates 3 times of 60% of 8-10 times of volume, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Bombyx Batryticatus extract.
(6) get Rhizoma Panacis Majoris, add 85% ethanol of 6-10 times of volume, 50-80 DEG C is extracted 3 times, each 1.5-3h, collects extracting solution and concentrates, obtaining rare extractum with 95% ethanol alcohol deposition method process concentrated solution; Above-mentioned rare extractum is crossed macroporous adsorbent resin, and first with the low-concentration ethanol eluting of water or 1-20%, removing is dissolved in the impurity of polar solvent, is discarded by the eluent of this water or low-concentration ethanol; Use the high concentration ethanol eluting of 40-95% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Rhizoma panacis majoris extract.
(7) get Thallus Laminariae (Thallus Eckloniae), add the 70% ethanol water room temperature percolation 3 days of 8-10 times of volume, filter, under filtrate room temperature condition, decompression rotates evaporate to dryness, obtains Thallus Laminariae (Thallus Eckloniae) extract.
(8) by above-mentioned Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae) extract mix homogeneously, various acceptable pharmaceutical dosage form is made.
According to the needs of the various drug form of preparation, medicine of the present invention also can add suitable pharmaceutic adjuvant as filler, disintegrating agent, binding agent, lubricant, antiseptic etc. in preparation process.
Preparation method of the present invention effectively can extract the effective ingredient in each crude drug, makes it better play the effect of Synergistic.
The present invention's various raw medicinal materials used are the Chinese crude drug meeting country or provincial standard and specify.The pharmaceutical composition of blood fat reducing of the present invention, based on theory of Chinese medical science, in conjunction with clinical practice, from Chinese medicine material treasure-house, filter out Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and the pure purification of tcm of Thallus Laminariae (Thallus Eckloniae) seven taste form, and regulate the weight of each raw material, and make the effect playing Synergistic between each raw material, can effectively blood fat reducing, heat clearing away suppressing the hyperactive liver, reduces phlegm and invigorates blood circulation.Pharmaceutical composition instant effect of the present invention simultaneously, dosage is little, has no side effect.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Embodiment 1
The pharmaceutical composition of the blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Et Rhizoma Rhei 9g, Radix Curcumae 9g, Fructus Crataegi 9g, Radix Polygoni Multiflori 9g, Bombyx Batryticatus 6g, Rhizoma Panacis Majoris 5g and Thallus Laminariae (Thallus Eckloniae) 3g.
Above-mentioned raw materials is prepared into granule, and preparation method is as follows:
(1) get Radix Et Rhizoma Rhei, add the water reflux, extract, 10 hours of 10 times of volumes, collect extracting solution, concentrated, dry, obtain Radix Et Rhizoma Rhei extract.
(2) get Radix Curcumae, add ethanol 55 DEG C of lixiviates 3 times of 80% of 10 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Curcumae extract.
(3) get Fructus Crataegi, pulverize, use mechanical lapping process, the water adding 10 times of volumes extracts 2 times at 35 DEG C, each 3h, merge extractive liquid, gets supernatant after centrifugal, adds ethanol to 60% and precipitates, centrifugal removing supernatant, collecting precipitation, vacuum lyophilization, obtains Fructus Crataegi extract.
(4) get Radix Polygoni Multiflori, add ethanol 60 DEG C of lixiviates 3 times of 80% of 8 times of volumes, each 2 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Polygoni Multiflori extract.
(5) get Bombyx Batryticatus, rub, add ethanol 50 DEG C of lixiviates 3 times of 60% of 8 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Bombyx Batryticatus extract.
(6) get Rhizoma Panacis Majoris, add 85% ethanol of 9 times of volumes, 60 DEG C are extracted 3 times, each 1.5h, collect extracting solution and concentrate, obtaining rare extractum with 95% ethanol alcohol deposition method process concentrated solution; Above-mentioned rare extractum is crossed macroporous adsorbent resin, first with water or 10% low-concentration ethanol eluting, removing is dissolved in the impurity of polar solvent, is discarded by the eluent of this water or low-concentration ethanol; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Rhizoma panacis majoris extract.
(7) get Thallus Laminariae (Thallus Eckloniae), add the 70% ethanol water room temperature percolation 3 days of 9 times of volumes, filter, under filtrate room temperature condition, decompression rotates evaporate to dryness, obtains Thallus Laminariae (Thallus Eckloniae) extract.
(8) by above-mentioned Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae) extract mix homogeneously, then add 150g dextrin, make granule according to the preparation technique of granule, be distributed into bag.
Embodiment 2
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Et Rhizoma Rhei 18g, Radix Curcumae 6g, Fructus Crataegi 3g, Radix Polygoni Multiflori 4g, Bombyx Batryticatus 10g, Rhizoma Panacis Majoris 2g and Thallus Laminariae (Thallus Eckloniae) 8g.
Above-mentioned raw materials is prepared into tablet, and preparation method is as follows:
(1) get Radix Et Rhizoma Rhei, add the water reflux, extract, 10 hours of 8 times of volumes, collect extracting solution, concentrated, dry, obtain Radix Et Rhizoma Rhei extract.
(2) get Radix Curcumae, add ethanol 55 DEG C of lixiviates 3 times of 80% of 8 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Curcumae extract.
(3) get Fructus Crataegi, pulverize, use mechanical lapping process, the water adding 10 times of volumes extracts 2 times at 35 DEG C, each 3h, merge extractive liquid, gets supernatant after centrifugal, adds ethanol to 60% and precipitates, centrifugal removing supernatant, collecting precipitation, vacuum lyophilization, obtains Fructus Crataegi extract.
(4) get Radix Polygoni Multiflori, add ethanol 60 DEG C of lixiviates 3 times of 80% of 8 times of volumes, each 2 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Polygoni Multiflori extract.
(5) get Bombyx Batryticatus, rub, add ethanol 50 DEG C of lixiviates 3 times of 60% of 8 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Bombyx Batryticatus extract.
(6) get Rhizoma Panacis Majoris, add 85% ethanol of 6 times of volumes, 50 DEG C are extracted 3 times, each 1.5h, collect extracting solution and concentrate, obtaining rare extractum with 95% ethanol alcohol deposition method process concentrated solution; Above-mentioned rare extractum is crossed macroporous adsorbent resin, first with water or 20% low-concentration ethanol eluting, removing is dissolved in the impurity of polar solvent, is discarded by the eluent of this water or low-concentration ethanol; Use the high concentration ethanol eluting of 65% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Rhizoma panacis majoris extract.
(7) get Thallus Laminariae (Thallus Eckloniae), add the 70% ethanol water room temperature percolation 3 days of 9 times of volumes, filter, under filtrate room temperature condition, decompression rotates evaporate to dryness, obtains Thallus Laminariae (Thallus Eckloniae) extract.
(8) by above-mentioned Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae) extract mix homogeneously, then with 120 starch, 15g polyvidone mixes, and adopts existing pressed-disc technique, makes the pharmaceutical composition of tablet.
Embodiment 3
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Et Rhizoma Rhei 5g, Radix Curcumae 20g, Fructus Crataegi 14g, Radix Polygoni Multiflori 12g, Bombyx Batryticatus 4g, Rhizoma Panacis Majoris 8g and Thallus Laminariae (Thallus Eckloniae) 2g.
Above-mentioned raw materials is prepared into powder, and preparation method is as follows:
(1) get Radix Et Rhizoma Rhei, add the water reflux, extract, 10 hours of 9 times of volumes, collect extracting solution, concentrated, dry, obtain Radix Et Rhizoma Rhei extract.
(2) get Radix Curcumae, add ethanol 55 DEG C of lixiviates 3 times of 70% of 9 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Curcumae extract.
(3) get Fructus Crataegi, pulverize, use mechanical lapping process, the water adding 9 times of volumes extracts 2 times at 35 DEG C, each 3h, merge extractive liquid, gets supernatant after centrifugal, adds ethanol to 60% and precipitates, centrifugal removing supernatant, collecting precipitation, vacuum lyophilization, obtains Fructus Crataegi extract.
(4) get Radix Polygoni Multiflori, add ethanol 60 DEG C of lixiviates 3 times of 80% of 9 times of volumes, each 2 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Polygoni Multiflori extract.
(5) get Bombyx Batryticatus, rub, add ethanol 50 DEG C of lixiviates 3 times of 60% of 9 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Bombyx Batryticatus extract.
(6) get Rhizoma Panacis Majoris, add 85% ethanol of 9 times of volumes, 70 DEG C are extracted 3 times, each 2h, collect extracting solution and concentrate, obtaining rare extractum with 95% ethanol alcohol deposition method process concentrated solution; Above-mentioned rare extractum is crossed macroporous adsorbent resin, first with water or 8% low-concentration ethanol eluting, removing is dissolved in the impurity of polar solvent, is discarded by the eluent of this water or low-concentration ethanol; Use the high concentration ethanol eluting of 60% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Rhizoma panacis majoris extract.
(7) get Thallus Laminariae (Thallus Eckloniae), add the 70% ethanol water room temperature percolation 3 days of 9 times of volumes, filter, under filtrate room temperature condition, decompression rotates evaporate to dryness, obtains Thallus Laminariae (Thallus Eckloniae) extract.
(8) by above-mentioned Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae) extract mix homogeneously, then with 150g dextrin, mixing, according to the preparation technique of powder, makes powder, is distributed into bag.
Embodiment 4
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Radix Et Rhizoma Rhei 10g, Radix Curcumae 5g, Fructus Crataegi 3g, Radix Polygoni Multiflori 6g, Bombyx Batryticatus 7g, Rhizoma Panacis Majoris 5g and Thallus Laminariae (Thallus Eckloniae) 2g.
Above-mentioned raw materials is prepared into capsule, and preparation method is as follows:
(1) get Radix Et Rhizoma Rhei, add the water reflux, extract, 10 hours of 10 times of volumes, collect extracting solution, concentrated, dry, obtain Radix Et Rhizoma Rhei extract.
(2) get Radix Curcumae, add ethanol 55 DEG C of lixiviates 3 times of 70% of 8 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Curcumae extract.
(3) get Fructus Crataegi, pulverize, use mechanical lapping process, the water adding 9 times of volumes extracts 2 times at 35 DEG C, each 3h, merge extractive liquid, gets supernatant after centrifugal, adds ethanol to 60% and precipitates, centrifugal removing supernatant, collecting precipitation, vacuum lyophilization, obtains Fructus Crataegi extract.
(4) get Radix Polygoni Multiflori, add ethanol 60 DEG C of lixiviates 3 times of 80% of 9 times of volumes, each 2 hours.Collect merge extractive liquid, and concentrate, dry, obtain Radix Polygoni Multiflori extract.
(5) get Bombyx Batryticatus, rub, add ethanol 50 DEG C of lixiviates 3 times of 60% of 8 times of volumes, each 1.5 hours.Collect merge extractive liquid, and concentrate, dry, obtain Bombyx Batryticatus extract.
(6) get Rhizoma Panacis Majoris, add 85% ethanol of 8 times of volumes, 70 DEG C are extracted 3 times, each 2.5h, collect extracting solution and concentrate, obtaining rare extractum with 95% ethanol alcohol deposition method process concentrated solution; Above-mentioned rare extractum is crossed macroporous adsorbent resin, first with water or 10% low-concentration ethanol eluting, removing is dissolved in the impurity of polar solvent, is discarded by the eluent of this water or low-concentration ethanol; Use the high concentration ethanol eluting of 65% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Rhizoma panacis majoris extract.
(7) get Thallus Laminariae (Thallus Eckloniae), add the 70% ethanol water room temperature percolation 3 days of 9 times of volumes, filter, under filtrate room temperature condition, decompression rotates evaporate to dryness, obtains Thallus Laminariae (Thallus Eckloniae) extract.
(8) by above-mentioned Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae) extract mix homogeneously, then with 25g vegetable oil, mixing, using ' Yanming ' capsules for clearing as capsule casing material, makes soft capsule.
Comparative example 1
The pharmaceutical composition of the blood fat reducing described in this comparative example, be made up of the raw material of following weight:
Radix Et Rhizoma Rhei 9g, Radix Curcumae 9g, Fructus Crataegi 9g, Radix Polygoni Multiflori 9g, Bombyx Batryticatus 6g and Thallus Laminariae (Thallus Eckloniae) 3g.
Adopt the preparation method described in embodiment 1, make the pharmaceutical composition of granule.
Comparative example 2
The pharmaceutical composition of the blood fat reducing described in this comparative example, be made up of the raw material of following weight:
Radix Et Rhizoma Rhei 9g, Radix Curcumae 9g, Fructus Crataegi 9g, Bombyx Batryticatus 6g, Rhizoma Panacis Majoris 5g and Thallus Laminariae (Thallus Eckloniae) 3g.
Adopt the preparation method described in embodiment 1, make the pharmaceutical composition of granule.
Embodiment 5
1. laboratory animal: healthy Kunming mouse, body weight 20-25g, male and female half and half;
2, Experimental agents: cholesterol, propylthiouracil.
3, experiment grouping:
Get healthy Kunming mouse 80, be divided into 8 groups at random, namely blank group, model group, positive drug group (administration simvastatin), embodiment 1 group (administration embodiment 1 prepare pharmaceutical composition), embodiment 2 groups (pharmaceutical composition prepared by administration embodiment 2), embodiment 3 groups (pharmaceutical composition prepared by administration embodiment 3), comparative example 1 group (pharmaceutical composition prepared by administration comparative example 1), comparative example 2 groups (pharmaceutical composition prepared by administration comparative example 2), often organize 10, male and female half and half.
Each group of morning gives gastric infusion, gavage solution is prepared with 2% tween solution, gavage capacity 20ml/kgBW, each group of embodiment 1-3, comparative example 1-2 respectively organize dosage and are 10g/kg by crude drug gauge, the dosage of simvastatin is 0.04g/kg, and blank, model group gives equivalent 2% tween solution.
4, experimental technique:
The preparation of 4.1 fat milks:
Get 1g propylthiouracil porphyrize in mortar, for subsequent use; Get 20g Adeps Sus domestica to melt in 40 DEG C of heating in water bath, put in mortar, add 10g cholesterol, 1g propylthiouracil, fully stir, dissolve; Slowly add 10% deoxycholic acid sodium water solution 20ml again, and constantly stir, then add 5ml Tween 80, grinding emulsifying is even, and last adding distil water is to 100ml; Load in hermetic container, cold preservation, obtains fat milk.Fat milk is melting prior to 37 DEG C of water-baths before use.
4.2 modeling methods: except blank group, all the other are respectively organized mice and all give gavage fat milk 20ml/kgBW, continuous 2 weeks.
5, Testing index
TG, TC level determination in 5.1 serum: after last gavage, water 12h is can't help in fasting, gets blood, according to test kit, mensuration TC, TG level is described.
MDA content and SOD determination of activity in 5.2 livers: mice is put to death after getting blood, wins liver 0.5g, rinses in normal saline, filter paper blots, make the liver homogenate liquid of 10% with normal saline homogenate, centrifuging and taking supernatant, illustrate according to test kit and measure MDA content and SOD activity.
6. statistical method: adopt SPSS13.0 software to carry out one factor analysis of variance to experimental data, every data all with
represent.
7, result:
7.1 impacts on serum TC, TG level: in table 1
Table 1: pharmaceutical composition of the present invention on the impact of mice serum TC, TG (
n=10)
| Group | Dosage (g/kg) | TC(mmol/L) | TG(mmol/L) |
| Normal group | / | 3.03±0.61 | 0.39±0.15 |
| Model group | / | 5.29±0.49 ## | 0.81±0.21 ## |
| Positive controls | 0.04 | 3.63±0.56 ** | 0.52±0.18 * |
| Embodiment 1 group | 10 | 3.70±0.48 **&▲ | 0.61±0.17 |
| Embodiment 2 groups | 10 | 3.92±0.57 **&▲ | 0.69±0.21 |
| Embodiment 3 groups | 10 | 3.96±0.52 **&▲ | 0.67±0.16 |
| Comparative example 1 group | 10 | 4.69±0.62 * | 0.72±0.17 |
| Comparative example 2 groups | 10 | 4.66±0.58 * | 0.70±0.18 |
Note: compare with normal group,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01; Compared with comparative example 1 group,
aMP.AMp.Ampp < 0.05; Compared with comparative example 2 groups,
▲p < 0.05.
Table 1 result shows:
Compare with normal group, in model group mice serum, TC and TG content is in various degree higher than normal group, and difference has statistical significance (P < 0.01), shows modeling success.
Compare with model group, positive controls reduces the content of TC, TG in mice serum, has significant difference (P < 0.01); Compare with model group, embodiment 1-3 group reduces TC and TG content, has significant difference (P < 0.01), shows that pharmaceutical composition of the present invention can effectively blood fat reducing.
Compare with 2 groups with comparative example 1, embodiment 1-3 respectively organizes TC and TG content in mice serum and obviously reduces (P < 0.05); Show in pharmaceutical composition of the present invention to be Synergistic between each raw material, lack effect that any Herba indigoferae Pseudotinctoriae all significantly can reduce pharmaceutical composition.
7.2 impacts on liver MDA content and SOD activity: in table 2
Table 2: on the impact of liver MDA content and SOD activity (
n=10)
| Group | Dosage (g/kg) | MDA(nmol/ml) | SOD(U/ml) |
| Normal group | / | 3.82±1.16 | 185.34±12.02 |
| Model group | / | 7.48±1.14 ## | 140.25±12.13 ## |
| Positive controls | 0.04 | 4.02±1.25 ** | 179.68±11.68 ** |
| Embodiment 1 group | 10 | 4.69±1.16 **&▲ | 175.52±11.65 **&▲ |
| Embodiment 2 groups | 10 | 4.92±1.22 **&▲ | 169.54±12.09 **&▲ |
| Embodiment 3 groups | 10 | 4.86±1.18 **&▲ | 170.26±11.58 **&▲ |
| Comparative example 1 group | 10 | 6.31±1.16 * | 152.31±11.74 * |
| Comparative example 2 groups | 10 | 6.28±1.19 * | 153.26±11.92 * |
Note: compare with normal group,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01; Compared with comparative example 1 group,
aMP.AMp.Ampp < 0.05; Compared with comparative example 2 groups,
▲p < 0.05.
Table 2 result shows:
Compare with normal group, in model group mouse liver, MDA content significantly raises, and SOD is active significantly reduces (P < 0.01), shows modeling success.
Compare with model group, positive controls MDA content obviously reduces, and SOD is active obviously raises (P < 0.01); Compare with model group, embodiment 1-3 group MDA content significantly reduces, and SOD is active significantly raises (P < 0.01), shows that pharmaceutical composition of the present invention can effectively blood fat reducing.
Compared with comparative example 1-2 group, embodiment 1-3 respectively organizes MDA content in mouse liver and obviously reduces, SOD is active obviously raises (P < 0.05), show in pharmaceutical composition of the present invention to be Synergistic between each raw material, lack effect that any Herba indigoferae Pseudotinctoriae all significantly can reduce pharmaceutical composition.
Claims (5)
1. the pharmaceutical composition for blood fat reducing containing Rhizoma Panacis Majoris, it is characterized in that, it is the medicament be made up of following raw material: Radix Et Rhizoma Rhei, Radix Curcumae, Fructus Crataegi, Radix Polygoni Multiflori, Bombyx Batryticatus, Rhizoma Panacis Majoris and Thallus Laminariae (Thallus Eckloniae).
2. pharmaceutical composition according to claim 1, it is characterized in that, the weight of described each raw material is: Radix Et Rhizoma Rhei 5 ~ 18 parts, Radix Curcumae 6 ~ 20 parts, Fructus Crataegi 1 ~ 15 part, Radix Polygoni Multiflori 4 ~ 15 parts, Bombyx Batryticatus 1 ~ 10 part, Rhizoma Panacis Majoris 1 ~ 10 part and Thallus Laminariae (Thallus Eckloniae) 1 ~ 8 part.
3. pharmaceutical composition according to claim 2, it is characterized in that, the weight of described each raw material is: Radix Et Rhizoma Rhei 6 ~ 15 parts, Radix Curcumae 6 ~ 14 parts, Fructus Crataegi 1 ~ 12 part, Radix Polygoni Multiflori 5 ~ 12 parts, Bombyx Batryticatus 4 ~ 8 parts, Rhizoma Panacis Majoris 2 ~ 7 parts and Thallus Laminariae (Thallus Eckloniae) 1 ~ 5 part.
4. pharmaceutical composition according to claim 3, it is characterized in that, the weight of described each raw material is: Radix Et Rhizoma Rhei 8 ~ 10 parts, Radix Curcumae 7 ~ 12 parts, Fructus Crataegi 5 ~ 10 parts, Radix Polygoni Multiflori 8 ~ 10 parts, Bombyx Batryticatus 5 ~ 6 parts, Rhizoma Panacis Majoris 3 ~ 6 parts and Thallus Laminariae (Thallus Eckloniae) 2 ~ 4 parts.
5. pharmaceutical composition according to claim 4, is characterized in that, the weight of described each raw material is: Radix Et Rhizoma Rhei 9 parts, Radix Curcumae 9 parts, Fructus Crataegi 9 parts, Radix Polygoni Multiflori 9 parts, Bombyx Batryticatus 6 parts, Rhizoma Panacis Majoris 5 parts and Thallus Laminariae (Thallus Eckloniae) 3 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626365.5A CN104367947A (en) | 2014-11-10 | 2014-11-10 | Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626365.5A CN104367947A (en) | 2014-11-10 | 2014-11-10 | Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104367947A true CN104367947A (en) | 2015-02-25 |
Family
ID=52547307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626365.5A Pending CN104367947A (en) | 2014-11-10 | 2014-11-10 | Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367947A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106139031A (en) * | 2016-08-22 | 2016-11-23 | 李双双 | A kind of Chinese medicine composition of blood fat reducing |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263717A (en) * | 1999-12-30 | 2000-08-23 | 高其品 | Health-care edible fungus tea and preparing process thereof |
| CN1451427A (en) * | 2003-04-08 | 2003-10-29 | 黄晓亚 | Hypotensive and hypolipemic tea |
| CN103393959A (en) * | 2013-08-09 | 2013-11-20 | 田艺儿 | Blood lipid-lowering traditional Chinese medicine formulation and preparation method thereof |
-
2014
- 2014-11-10 CN CN201410626365.5A patent/CN104367947A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263717A (en) * | 1999-12-30 | 2000-08-23 | 高其品 | Health-care edible fungus tea and preparing process thereof |
| CN1451427A (en) * | 2003-04-08 | 2003-10-29 | 黄晓亚 | Hypotensive and hypolipemic tea |
| CN103393959A (en) * | 2013-08-09 | 2013-11-20 | 田艺儿 | Blood lipid-lowering traditional Chinese medicine formulation and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王世钦等主编: "《高脂血症中医防治与养生》", 31 January 2010, 化学工业出版社 * |
| 盛燕儿等: "自拟泻脂汤治疗低密度脂蛋白胆固醇血症47例", 《浙江中西医结合杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106139031A (en) * | 2016-08-22 | 2016-11-23 | 李双双 | A kind of Chinese medicine composition of blood fat reducing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN104645232A (en) | Traditional Chinese medicine combinatorial composition for treatment of double-flexure syndrome and preparation method and applications thereof | |
| CN104435772A (en) | Hawthorn-containing pharmaceutical composition for reducing blood fat | |
| CN104367947A (en) | Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat | |
| CN108143833A (en) | A kind of preparation method of licorice piece | |
| CN103446445A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN102526639A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN100346821C (en) | Medicinal capsule for treating liver and gallbladder diseases and its preparing process | |
| CN104435205A (en) | Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat | |
| CN104338052A (en) | Formula of traditional Chinese medicine for treating cerebral thrombosis | |
| CN104352667A (en) | Medicine for treating nonspecific vaginitis and preparation method | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN103751650A (en) | Traditional Chinese medicinal composition for treating remission of gout and preparation method thereof | |
| CN104367642A (en) | Polygonum multiflorum-containing pharmaceutical composition for lowering blood fat | |
| CN105148067A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN105287798A (en) | Lipid-lowering and slimming recovery pill | |
| CN104367731A (en) | Plantain seed-containing pharmaceutical composition for lowering blood fat | |
| CN104997881A (en) | Decoction medicine capable of treating productive spondylitis and preparation method thereof | |
| CN104367840A (en) | Astragalus root-containing pharmaceutical composition for lowering blood fat | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN104435877A (en) | Radix-puerariae-containing pharmaceutical composition for reducing blood fat | |
| CN104367653A (en) | Codonopsis pilosula-containing pharmaceutical composition for lowering blood fat | |
| CN113209251A (en) | Traditional Chinese medicine composition, preparation method and application of traditional Chinese medicine composition in preparation of antitumor drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150225 |